EVE Completes R&D on Oral Sprays and Apixaban Reformulation Targeting $30B Markets

EVE Advances Reformulation Strategy

EVE Health Group (ASX:EVE) has announced the completion of research and development on several reformulated pharmaceutical candidates targeting significant global markets in sexual health and cardiovascular therapies. Leveraging its proprietary drug delivery and solubilisation technologies, EVE aims to improve the delivery and patient experience of established medicines approaching patent expiry.

The company’s approach focuses on reformulating well-known drugs with proven safety profiles, enhancing bioavailability, onset of action, and convenience. This strategy mitigates the risks and timelines typically associated with novel drug discovery, while opening access to large, predictable markets.

Targeting Men’s Sexual Health with Innovative Sprays

EVE has developed three proprietary oral spray formulations addressing erectile dysfunction and premature ejaculation, conditions with combined global markets exceeding US$8 billion annually. These include a rapid-delivery, alcohol-free vardenafil spray designed to improve onset and efficacy, a dapoxetine spray aiming to overcome dosing limitations of current treatments, and a novel dual-molecule spray combining both active ingredients for patients experiencing both conditions.

These formulations are poised to offer enhanced patient compliance and convenience, potentially reshaping treatment paradigms in men’s sexual health. Patent applications are being prepared to protect these innovations ahead of commercialisation efforts.

Expanding into Cardiovascular Therapies with Apixaban Reformulation

Beyond sexual health, EVE has also reformulated apixaban, a leading anticoagulant with global sales surpassing US$19 billion. The reformulation focuses on improving solubility and enabling alternative dosage forms such as liquids or orally dissolvable formats, addressing swallowing difficulties common among the estimated 590 million people worldwide affected by dysphagia.

This development could enhance treatment accessibility and adherence for patients requiring anticoagulation therapy, particularly as apixaban’s primary patents approach expiry between 2026 and 2028.

Commercialisation and Licensing Outlook

EVE plans to capitalise on these reformulations through licensing partnerships with established pharmaceutical companies possessing regulatory, manufacturing, and distribution capabilities. This model allows EVE to focus on innovation while leveraging partners’ commercial infrastructure to scale market access efficiently.

With several blockbuster drugs nearing patent cliffs, EVE’s pipeline expansion positions the company as a compelling partner for pharmaceutical firms seeking differentiated formulations to sustain market share and meet evolving patient needs.

Chief Operating Officer Ben Rohr emphasised the strategic significance of these advancements, highlighting the expanded commercial opportunities and validation of EVE’s technology platform as the company moves toward licensing discussions.